| The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases JW Harper, GR Adami, N Wei, K Keyomarsi, SJ Elledge Cell 75 (4), 805-816, 1993 | 7774 | 1993 |
| Inhibition of cyclin-dependent kinases by p21. JW Harper, SJ Elledge, K Keyomarsi, B Dynlacht, LH Tsai, P Zhang, ... Molecular biology of the cell 6 (4), 387-400, 1995 | 1376 | 1995 |
| Role of cell cycle in mediating sensitivity to radiotherapy TM Pawlik, K Keyomarsi International Journal of Radiation Oncology* Biology* Physics 59 (4), 928-942, 2004 | 1332 | 2004 |
| Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase DM Koepp, LK Schaefer, X Ye, K Keyomarsi, C Chu, JW Harper, ... Science 294 (5540), 173-177, 2001 | 967 | 2001 |
| Cyclin E and survival in patients with breast cancer K Keyomarsi, SL Tucker, TA Buchholz, M Callister, YE Ding, ... New England Journal of Medicine 347 (20), 1566-1575, 2002 | 753 | 2002 |
| Redundant cyclin overexpression and gene amplification in breast cancer cells. K Keyomarsi, AB Pardee Proceedings of the National Academy of Sciences 90 (3), 1112-1116, 1993 | 722 | 1993 |
| Synchronization of Tumor and Normal Cells from G1 to Multiple Cell Cycles by Lovastatin K Keyomarsi, L Sandoval, V Band, AB Pardee Cancer research 51 (13), 3602-3609, 1991 | 584 | 1991 |
| Cyclin E, a potential prognostic marker for breast cancer K Keyomarsi, N O'Leary, G Molnar, E Lees, HJ Fingert, AB Pardee Cancer research 54 (2), 380-385, 1994 | 538 | 1994 |
| Differential display and cloning of messenger RNAs from human breast cancer versus mammary epithelial cells P Liang, L Averboukh, K Keyomarsi, R Sager, AB Pardee Cancer Research 52 (24), 6966-6968, 1992 | 537 | 1992 |
| Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase S Rao, DC Porter, X Chen, T Herliczek, M Lowe, K Keyomarsi Proceedings of the National Academy of Sciences 96 (14), 7797-7802, 1999 | 446 | 1999 |
| Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53 SS Bacus, AV Gudkov, M Lowe, L Lyass, Y Yung, AP Komarov, ... Oncogene 20 (2), 147-155, 2001 | 436 | 2001 |
| Transcriptional downregulation of gap-junction proteins blocks junctional communication in human mammary tumor cell lines. SW Lee, C Tomasetto, D Paul, K Keyomarsi, R Sager The Journal of cell biology 118 (5), 1213-1221, 1992 | 345 | 1992 |
| Deregulation of cyclin E in breast cancer. K Keyomarsi, D Conte Jr, W Toyofuku, MP Fox Oncogene 11 (5), 941-950, 1995 | 323 | 1995 |
| Atypical PKCι contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer AM Eder, X Sui, DG Rosen, LK Nolden, KW Cheng, JP Lahad, ... Proceedings of the National Academy of Sciences 102 (35), 12519-12524, 2005 | 305 | 2005 |
| Differential mRNA expression of the human DNA methyltransferases (DNMTs) 1, 3a and 3b during the G0/G1 to S phase transition in normal and tumor cells KD Robertson, K Keyomarsi, FA Gonzales, M Velicescu, PA Jones Nucleic acids research 28 (10), 2108-2113, 2000 | 267 | 2000 |
| CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers S Vijayaraghavan, C Karakas, I Doostan, X Chen, T Bui, M Yi, ... Nature communications 8 (1), 15916, 2017 | 261 | 2017 |
| Expression of cytochromes P450 in human breast tissue and tumors. Z Huang, MJ Fasco, HL Figge, K Keyomarsi, LS Kaminsky Drug metabolism and disposition 24 (8), 899-905, 1996 | 246 | 1996 |
| An efficient deletion mutant packaging system for defective herpes simplex virus vectors: potential applications to human gene therapy and neuronal physiology. AI Geller, K Keyomarsi, J Bryan, AB Pardee Proceedings of the National Academy of Sciences 87 (22), 8950-8954, 1990 | 239 | 1990 |
| Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells K Keyomarsi, RG Moran Cancer research 46 (10), 5229-5235, 1986 | 239 | 1986 |
| Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53 S Rao, M Lowe, TW Herliczek, K Keyomarsi Oncogene 17 (18), 2393-2402, 1998 | 236 | 1998 |
